Clinical and MRI characteristics and follow-up studies of insulin-derived amyloidosis

Nagase, Terumasa; Iwaya, Keiichi; Zako, Tamotsu; Odaka, Tomotada; Kogure, Koichiro; Nemoto, Yuta; Misumi, Yohei; Noritake, Masayuki; Ando, Yukio; Katsura, Yoshiya

doi:10.1080/13506129.2019.1582517

Cited by 6 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mechanism resulting in the difference between insulin‐derived amyloidosis with and without palpable masses is unknown. The clinical features of the two present patients were compared with those of 14 patients with insulin‐derived amyloidosis with palpable masses. The features including the durations of diabetes and insulin therapy, glycated hemoglobin, and total daily insulin dose were not significantly different between the two groups, although age was slightly higher than in the present cases ( P = 0.089).…”

Section: Discussionmentioning

confidence: 54%

“…This report showed that insulin‐derived amyloidosis can be present at insulin injection sites without a palpable mass. Before having seen these two patients, we had treated 14 patients with insulin‐derived amyloidosis, all of whom had the amyloid deposits as palpable masses at insulin injection sites. Only one report presented three cases with insulin‐derived amyloidosis who did not have local masses, in whom abdominal fat aspiration was carried out for the diagnosis of suspected systemic amyloidosis, and mass spectrometry analyses unexpectedly showed insulin within the amyloid deposits.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Insulin‐derived amyloidosis without a palpable mass at the insulin injection site: A report of two cases

Nagase

Iwaya

Kogure

et al. 2020

J of Diabetes Invest

Self Cite

View full text Add to dashboard Cite

To date, almost all case reports of insulin-derived amyloidosis described the presence of a subcutaneous mass that was observable on physical examination. This report presents two cases of insulin-derived amyloidosis without palpable masses at insulin injection sites. In both cases, blood glucose concentrations improved, and the insulin dose could be reduced by an average of 45% after changing the insulin injection sites. The insulin absorption at the site was reduced to at most 40% of that at a normal site in one case. Magnetic resonance imaging and ultrasonography were useful to screen and differentiate insulin-derived amyloidosis without a palpable mass. This report showed that insulinderived amyloidosis without a palpable mass can be present at the insulin injection site, and has similar clinical effects to insulin-derived amyloidosis with palpable masses.

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Discussionmentioning

confidence: 99%

Insulin‐derived amyloidosis without a palpable mass at the insulin injection site: A report of two cases

Nagase

Iwaya

Kogure

et al. 2020

J of Diabetes Invest

Self Cite

View full text Add to dashboard Cite

show abstract

“…Самой частой формой локального амилоидоза является амилоидоз пред сердий, обусловленный отложением предсердного натрийуретичес кого фактора (AANF-амилоидоз) [7]. Известна также ятрогенная форма локального амилоидоза, вызванного отложением инсулина в местах введения препарата больным сахарным диабетом [8,9].…”

Section: проблемы диагностики и лечения локального Al-амилоидозаunclassified

Diagnosis and treatment of localized AL-amyloidosis

Pan¹,

Рамеев²,

Rameeva³

et al. 2019

CPT

View full text Add to dashboard Cite

“…Insulin-derived amyloidosis is a disease characterized by the formation of amyloid fibril deposits in tissues and organs as a complication of diabetic therapy with insulin and its analogues [ 1 – 3 ]. The number of detected clinical cases has increased in recent years, and their prevalence may still be insufficiently diagnosed and underestimated [ 4 , 5 ]. Insulin amyloids have demonstrated toxicity in vivo [ 6 ], and insulin-induced amyloidosis creates poor glycaemic control [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Determination of amyloid core regions of insulin analogues fibrils

Surin

Grishin

Galzitskaya

2020

Prion

View full text Add to dashboard Cite

A rapid-acting insulin lispro and long-acting insulin glargine are commonly used for the treatment of diabetes. Clinical cases have described the formation of injectable amyloidosis with these insulin analogues, but their amyloid core regions of fibrils were unknown. To reveal these regions, we have analysed the hydrolyzates of insulin fibrils and its analogues using high-performance liquid chromatography and mass spectrometry methods and found that insulin and its analogues have almost identical amyloid core regions that intersect with the predicted amyloidogenic regions. The obtained results can be used to create new insulin analogues with a low ability to form fibrils. Abbreviations: a.a., amino acid residues; HPLC-MS, high-performance liquid chromatography/ mass spectrometry; m/z, mass-to-charge ratio; TEM, transmission electron microscopy.

show abstract

Clinical and MRI characteristics and follow-up studies of insulin-derived amyloidosis

Cited by 6 publications

References 3 publications

Insulin‐derived amyloidosis without a palpable mass at the insulin injection site: A report of two cases

Insulin‐derived amyloidosis without a palpable mass at the insulin injection site: A report of two cases

Diagnosis and treatment of localized AL-amyloidosis

Determination of amyloid core regions of insulin analogues fibrils

Contact Info

Product

Resources

About